Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy

Fig. 2

Patients with normalized HAQ-DI scores/HAQ-DI MCID at month 12, categorized by CDAI remission and LDA. Plots show a patients with normalized HAQ-DI scores (< 0.5) at month 12 and b patients achieving HAQ-DI MCID (decrease from baseline of ≥ 0.22) at month 12, categorized by CDAI remission/LDA (≤ 10) status at months 6 and 12, and c patients with normalized HAQ-DI scores (< 0.5) at month 12 and d patients achieving HAQ-DI MCID (decrease from baseline of ≥ 0.22) at month 12, categorized by TA-CDAI remission/LDA and moderate/high disease activity status. TA-CDAI was defined as CDAI AUC divided by 12. ADA, adalimumab; AUC, area under the curve; CDAI, Clinical Disease Activity Index; HAQ-DI, Health Assessment Questionnaire-Disability Index; LDA, low disease activity; MCID, minimum clinically important difference; MTX, methotrexate; TA, time-averaged; SE, standard error

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us